Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial

Mingyu Si 1, Xiaoyou Su 1*, Yu Jiang 1, Youlin Qiao 2 and Yuanli Liu 1

Abstract

Background: While the HPV vaccines have been approved by the US FDA since 2006, in recent years an increasing number of women are living with cervical cancer globally. Among them, Chinese women have a higher cervical cancer incidence and mortality rate than the global average, with mortality rates being almost twice the global average. However, the current approach of HPV vaccination in China is not satisfactory given the high disease burden of cervical cancer. The current study is a randomized controlled trial designed to identify the barriers and facilitators of HPV vaccination among Chinese female students. This study will also test a health intervention measure via a popular form of new media in order to improve the HPV vaccine uptake under the framework of Information-Motivation-Behavioral skill Model (IMB).

Methods: This investigation is a multicenter, school-based, prospective, randomized, parallel group, double-blind, blank-controlled trial involving a 7-day education intervention with a further 6-month follow-up. We will enroll at least 3360 participants older than 18 years. The enrolled participants will be randomly divided into two groups (1:1 ratio). The intervention group will be offered a 7-day mobile health education, and participants in both groups will fill out 4 questionnaires at the baseline, 1 month, 3 months and 6 months after the intervention. The primary outcome is the difference in HPV vaccination or reservation for the HPV vaccine between the intervention and control groups. Secondary outcomes will include the comparison of (1) knowledge, attitudes, motivation, beliefs and behavioral skill about HPV and cervical cancer prevention, and (2) the willingness to uptake HPV vaccination.

Discussion: This study will examine the theory-based intervention in improving HPV vaccination among Chinese female college students. We will conduct the randomized controlled trial to provide scientific evidence on the potential effect of the IMB theory-based intervention. Findings from this study will contribute to a growing research field which assesses the effectiveness of mobile-based, school-targeted and theoretically guided interventions for promoting HPV vaccination in adolescents.

Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR1900025476; Registered on 27 August 2019.

Keywords: Human papillomavirus, HPV, Cervical cancer, Vaccination, Intervention, IMB, Chinese, Female

* Correspondence: suxiaoyou@hotmail.com

1School of Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 DongDanSanTiao, Dongcheng District, Beijing, China

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Globally, cervical cancer is the fourth most common malignant tumor in women, with an incidence of about 6.6% and a mortality rate of 7.5% [1]. In 2018, about 570,000 new cases of cervical cancer were diagnosed and 310,000 deaths were reported [1]. Among these, low and middle-income countries account for 86% of new cases and 88% of deaths worldwide [1]. In China, cervical cancer is more prevalent than the global average, with the cancer being the second most common malignant tumor among Chinese women [2]. In 2018, the age-standardized incidence rate of cervical cancer among Chinese females was still as high as 10.7% [3], although China has introduced HPV2 (Cervarix), HPV4 (Gardasil) and HPV9 (Gardasil) to the mainland between 2016 to 2018 to cope with the burden of cervical cancer caused by HPV-16 and HPV-18 [4].

While the safety and efficacy of the HPV vaccine has been widely recognized by authoritative organizations and institutions, HPV vaccination rates are still low in mainland China [5–10]. Data from the National Cancer Center suggests that a lack of knowledge on HPV and cervical cancer may be a barrier to HPV vaccination [10, 11]. Studies have also found that Chinese adolescents have a low awareness of HPV vaccination [12, 13]. Other barriers to cancer prevention for Chinese women include cultural beliefs on sexuality and widespread vaccine hesitation or rejection due to misconceptions about HPV prevention [14, 15]. In addition, HPV vaccination has not been publicly provided in China. Instead, citizens must pay for the HPV vaccine at their own expense.

Despite the importance of the HPV vaccine for cervical cancer prevention, limited information has been available on how to improve HPV vaccination among Chinese people [16, 17]. Before the HPV vaccine got approved in mainland China, an intervention study conducted in the junior middle schools of Chengdu, China, found an increase in student willingness to be vaccinated from 56.5 to 88.4% (p < 0.001) after 1-h of health education [16]. Similar to the school-based study, the HPV vaccine acceptability has also been observed to increase among employed women and female undergraduate students after an informative group lecture [17]. However, the results of the above mentioned studies did not include the HPV vaccination rate as one of the assessment indices of the intervention. Thus, there is an urgent need to develop effective intervention strategies to improve HPV vaccination among Chinese women, especially using the HPV vaccine uptake as the primary outcome.

Results from the successful promotion experiences of the HPV vaccine abroad suggest that employing culturally tailored and theory-based education could positively influence participants to receive the HPV vaccine, especially if school-based intervention is targeted at adolescent females [18, 19]. Perhaps this is due to a combination of cultural ideals valuing school as a place for students to gain new knowledge, the emerging sexual needs of students and the higher HPV infection rate among adolescents [20–22]. In addition, given the widespread usage of mobile phones among young adults and the ability of mobile phone technology to overcome location and time restrictions, a mobile-based health intervention could be a low-cost and effective method to reach populations with low HPV vaccination rates [23, 24].

Given the emerging need for increased HPV vaccination among Chinese women in recent years, the current study will test the effects of a mobile-based intervention on Chinese female college students (see Fig. 1 for conceptual framework), guided by the Information- Motivation- Behavior skill model (IMB) [25]. Specifically designed for the HPV vaccine uptake study, the IMB model constructs used in this study include information relating to HPV and the HPV vaccine for cervical cancer prevention, HPV vaccination motivation, and some useful behavioral skills to ensure HPV vaccination [26].

We hypothesize that a mobile-based approach combining theory-based education and information about HPV, cervical cancer and the HPV vaccine may significantly improve HPV vaccination rates among participants.

Therefore, the primary objective of this study is to investigate the efficacy of a 7-day mobile-based intervention designed to increase HPV vaccination among Chinese female college students. The secondary objectives are to: (1) explore the impact of the intervention on knowledge, attitudes, and beliefs about HPV, cervical cancer and the HPV vaccine, (2) evaluate the short-term effect on uptake intention of the HPV vaccine, (3) determine the factors associated with the willingness of vaccination uptake and (4) identify the factors influencing HPV vaccination.

Methods/design

Trial design

This is a multicenter, school-based, prospective, randomized, parallel group, double-blind, blank controlled trial involving a 7-day education intervention with a further 6 months follow-up. A total of 3360 individuals over 18 years old will be randomized to: (1) intervention group: this group will receive a baseline questionnaire followed by a 7-day mobile health education, and 3 questionnaire surveys at 1 month, 3 months, and 6 months after the intervention, or (2) control group: this group will receive 4 questionnaire surveys conducted
simultaneously with the intervention group. This study protocol is reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement, and results will be reported in line with the Consolidated Standards of Reporting Trials (CONSORT) statement and the CONSORT statement for non-pharmacological interventions [27–29].

Study setting
To ensure the representativeness of the research findings, we will recruit participants from seven comprehensive universities located in seven geographical territories of China: Shandong University in East China, Zhongshan University in South China, Zhengzhou University in Central China, Capital Normal University in North China, Sichuan University in Southwest China, Dalian University of Technology in Northeast China, and Xinjiang University in Northwest China. The reasons for selecting these colleges is that they are located in cities with relatively advanced political and economic levels in their respective geographical territories and are all top-ranking comprehensive universities. Thus, the research settings can ensure the balance of background features to a large extent. All researchers and support staff in this
project will be trained based on the same training protocols and are required to have an educational background in public health. This study follows the regulations of Measures for the Ethical Review of Biomedical Research Involving Humans (Implemented on December 1, 2016) of the National Health Commission of the People’s Republic of China. All participants will sign an informed consent after they agree to attend the study and before the baseline survey. This study is planned to be carried out in November 2019 and last for about 7 months.

Participants
Suitable participants will be screened at each center for their eligibility to participate in the study:

The inclusion criteria are as follows: (1) females over 18 years of age; (2) first and second-year undergraduate students; (3) no vaccination contraindications; (4) having mobile phone or computer access.

The exclusion criteria are as follows: (1) males; (2) females under 18; (3) non-undergraduate first or second-year students; (4) medical students; (5) previous history of vaccination contraindications; (6) current pregnancy or breast feeding.

Recruitment and informed consent
All enrolled participants will be informed of the research objectives, the study procedures, their rights and obligations, the expected benefits and the possible risks to the participants before they sign the informed consents (Appendix). Participants in the study will also have the right to freely obtain more information at any time and will be allowed to freely withdraw from the study without restrictions at any research stage.

Once each participant signs the informed consent, the researchers will complete the eligibility checklists and records will be made of any candidate who fails to meet the inclusion criteria. Additionally, in order to facilitate follow-up services, we need participants to leave a mobile phone number or WeChat account. All of the above information is stored on an encrypted laptop and kept by a dedicated person with strict information confidentiality.

Sampling and randomization
The study process consists of the following four phases:

Phase 1: Confirm the stratified sampling framework by geographical territories of China.

The stratified sampling of the 31 provinces/municipalities/autonomous regions in China is conducted from seven geographical territories, namely East China, South China, Central China, North China, Northwest China, Southwest China and Northeast China.

Phase 2: Convenient sampling to determine the cities and universities to be included within the geographic territories in Phase 1.

We select a representative city in each of the seven geographical territories using the convenient sampling method. A total of 7 cities (Jinan of Shandong Province, Guangzhou of Guangdong Province, Zhengzhou of Henan Province, Beijing, Urumqi of Xinjiang Uygur Autonomous Region, Chengdu of Sichuan Province, Dalian of Liaoning Province) were finally decided to be the study sites. In each representative city, a comprehensive university is selected. A total of 7 universities (Shandong University, Zhongshan University, Zhengzhou University, Capital Normal University, Xinjiang University, Sichuan University, Dalian University of Technology) are finally confirmed as research centers for this study.

Phase 3: Cluster sampling in each of the seven research centers.

After satisfying the inclusion criteria, at least 240 university students will be selected by class from the literature and science majors (excluding medical majors) respectively, and a total of 480 samples will be composed at each of the seven centers. This selection will result in a total of at least 3360 participants across 7 schools.

Phase 4: Randomization and allocation in each center.

After the baseline survey, all identified participants will be randomly assigned to the intervention group or control group in a 1:1 ratio, and each group at each center will have 240 participants. Randomization will be stratified with regards to majors, resulting in two separate categories of literature and science majors. The random sequence will be generated using SAS V.12. (SAS Institute) software. Furthermore, randomization will be conducted by personnel not involved in the trial at each of the seven universities.

After randomization, the researcher who assigns participants to the intervention will provide information about the mobile-based education. This researcher will no longer be blinded from this point.

Blinding
In this investigation, all researchers involved in outcome assessments will be blinded to the group allocation of participants. During the intervention period, only unblinded researchers will be in contact with participants enrolled in the trial. In addition, all data analysis will be completed by personnel who are blinded to the intervention assignment. Participants will be unblinded after the 6 months and 7 days of assessment.

Interventions
Theory-based educational measures delivered by a smart application
We developed the contents of the digital multimedia education intervention after reviewing the related literature and conducting several rounds of panel discussions. The panel members included a Cancer Epidemiologist, an Infectious Diseases Epidemiologist, a Senior Manager in a new media company and a researcher from one of the research centers of this project. We also formed a University advisory committee, which consisted of the project leader of each sub-center, authoritative experts in the field of cervical cancer prevention and treatment, and experienced experts in the field of epidemiology and health statistics. Additionally, we conducted a series of focus groups with 50 undergraduate girls and key information interviews with university counselors and health professionals. During such time we modified and refined the intervention content and finally determined that the best format to deliver the 7-day education intervention would be via smart devices such as a computer or mobile phone.

According to the IMB, mobile health intervention popularizes health-related knowledge, develops motivators to raise awareness of healthy behavior, and provides relevant behavioral skills that actually shape specific health behaviors (ie, injection of the HPV vaccine) [26] (see Fig. 1). The educational content of the mobile health intervention will cover the following topics: (1) basic health knowledge including information on the prevention of infectious diseases, vaccination, and sexual health, (2) information on HPV infection, cervix and cervical cancer, and the incidence and mortality rates of cervical cancer among Chinese women compared to the world average level, (3) introduction of the HPV vaccine as a preventive measure for cervical cancer, (4) case study showing the prognosis of Chinese women with advanced cervical cancer, (5) a story telling the experience of a female college student from being unaware of HPV to making a decision to vaccinate against HPV, (6) information on how to improve self-efficacy and self-determination in order to improve healthy behavior, and (7) behavioral techniques for HPV vaccination, including information on the availability and cost of the HPV vaccine at local clinics. The mobile health intervention will be delivered to each participant over 10 min each day for a 7-day period at each participant’s preferred time.

The mobile health intervention contains a high level of interactivity. Participants will be allowed to engage in mutual conversation amongst themselves on different topics of intervention. Based on the mobile application, the intervention group and the control group at each center will establish a chat group respectively, and the administrator will automatically upload 10 min of educational content in the intervention chat group only. After completing the learning session, participants can perform punching and talk about the educational content.

Control group (no intervention/ black control).

Compliance

Attendance records will be used to assess the participants’ compliance with the intervention. This will occur the following day after each new educational content is uploaded. Furthermore, the number of participants in each questionnaire will be used to assess the participants’ compliance with the entire trial process.

Procedure

To satisfy the study assessments, participants will complete a total of four electronic questionnaires (see Fig. 2). Electronic surveys will be carried out at approximately the same time (within 1 h) among the participants.

Screening

Potential participants will be identified for inclusion/exclusion criteria and those who are eligible will be provided with a written informed consent form. Individuals who agree to attend the study will be briefed on the function of the mobile app and core study measures.

Baseline

Prior to the intervention, the baseline survey will be conducted to assess socio-demographic and HPV vaccination status, sexual history, and knowledge, attitudes and beliefs about HPV and HPV vaccination.

Intervention procedure

Upon completion of the baseline assessment, two research staff will anonymize and number the students. The staff will then randomize participants to either the intervention group or control group. The intervention and control group will have at least 240 participants respectively at each of the seven centers. Timing randomization in this way ensures we can balance intervention and control groups on baseline characteristics. One unblinded research staff will remain in contact with participants via the mobile app. The intervention group will receive digital education materials every day during the 7-day intervention period, while the control group will not have any form of intervention. Possible intervention non-attendance and trial non-compliance will be collected and followed up via telephone by the unblinded researcher.

1-month follow-up

The participants in both the intervention and control groups will be followed up via the mobile app at 1 month after the intervention, and a questionnaire will be conducted simultaneously. Their HPV vaccination status and HPV related knowledge will be assessed. Likewise,
their personal motivation, intention and relevant behavioral skills regarding the injection of the HPV vaccine will also be examined. In addition, the intervention group will assess their satisfaction with the intervention.

**3-month follow-up**
All measures from the 1-month questionnaire will be repeated in both groups, except for the satisfaction assessment of the intervention.

6-month follow-up: All measures from the 3-month questionnaire will be repeated in both groups, along with reasons for vaccination refusal inquiry, if required.

**Measures**
We will collect information from participants using a structured electronic questionnaire administered at four time points: at the study enrollment (baseline), 1 month after completing the digital education intervention (post-test), 3 months after the intervention and 6 months after the intervention (follow-up).

**Outcome measures**
Our primary outcomes of interest will be the difference between the intervention and the control group, which include: (1) knowledge, attitudes and beliefs about HPV, cervical cancer and the HPV vaccine; (2) intent to uptake the HPV vaccine; and (3) the reception of or an appointment for the first dose of the HPV vaccine.

**Baseline measures**
We will collect participants’ HPV vaccination status, socio-demographic information (date of birth, nationality, religion, habitual residence, economic status, parental employment and marital status, and family or friends’ cancer history), health and sexual history. We will also record information about knowledge, cognition and beliefs related to HPV and HPV vaccination, motivations and intentions to uptake the HPV vaccine, decision-making, self-efficacy and objective skills regarding HPV vaccination. For background information, we will refer to the relevant part of several related studies conducted in China previously. The 11-item scale from Kahn JA and the HAVIQ (HPV Adolescent Vaccine Intervention Questionnaire) from Forster AS will be partly used to measure knowledge about HPV and HPV vaccination [30, 31]. For measuring cognition of HPV infection and prevention, we will use scales from Kim HW, Gerend MA and Guvenc G [32–34]. This will assess the perceived severity of HPV infection and the perceived benefits and barriers of HPV vaccination. Two scales from Ralph will be used to measure the perceived susceptibility of HPV infection [35]. The 5-item scale from Gerend MA will be adopted to test the influence of subjective norms [33]. For measuring decision-making for health protection, we will use the 3-item scale of Forster AS [31]. Self-efficacy for completing the 3-dose HPV vaccination will be tested using the 4-item scale of Gerend MA [33]. The self-administered 4-item scale developed by Fisher will also be used to measure the objective skills needed to initiate and complete HPV vaccination [26]. Finally, intent to receive the HPV vaccine will be measured according to the answer to the question: “Willingness to take the HPV vaccine in the next 6 months”.

**Post-test measures**
At the 1-month follow-up, we will administer a post-test survey of the same information collected at the baseline, except for background information. Furthermore, we will measure participant satisfaction with the mobile app-based education to provide information for improving similar studies in the future.

**Follow-up measures**
At the 3-month follow-up, excluding the satisfaction assessment of the intervention, we will measure the same items collected during the 1-month follow-up test. For participants not receiving or ordering a dose of the HPV vaccine during the trial period, we will ask for the reasons for vaccine hesitation or refusal at the 6-month follow-up survey.

**Sample size calculation**
To date, no studies have investigated the effects of a mobile app-based intervention with Chinese female college students to improve the HPV vaccine uptake. For this reason, the anticipated effect size is largely based on findings derived from similar research literature in other countries. This study will apply a two-tail test with \( \alpha = 0.05 \) and \( \beta = 0.20 \). Statistical power was originally calculated based on an absolute difference of 10% (20% of girls in the intervention group relative to 10% of girls in the control condition would initiate vaccination). The number of cases needed in each group of each sub-center is 119 as calculated by Statistical Analysis System (SAS) V.12. Allowing for a 20% rate of loss to follow-up, 240 cases are required in each group, and a total of 480 cases are required for each trial center. Consequently, this study requires a total of at least 3360 participants in 7 schools.

**Statistical analysis**
Since the study collects data through electronic questionnaires, there will be no formal data monitoring committee. Participants fill out the questionnaire and automatically upload it to a read-only database to ensure the authenticity of the data; however, all data will be reviewed by the research team at regular intervals throughout the study.

We will conduct all analysis using IBM SPSS Statistics 22.0, Version 22.0. Data will be checked for internal consistency and logic prior to further analysis.
intention-to-treat analysis will be performed. Descriptive statistics of all variables will be calculated, including means and standard deviations or frequencies as appropriate. We will assess the potential bias in enrollment and follow-up by comparing characteristics using a Wilcoxon Rank Sum, chi-squared, or Fisher Exact test as appropriate.

Proportions of qualitative variables will be compared between the intervention and control groups using chi-squared tests at baseline and repeated at 1 month, 3 months and 6 months after intervention. For each of these measures, the change in proportion from the baseline to these 3 point-ends will be tested within intervention groups using McNemar's tests. Unadjusted odds of vaccine uptake and intent to vaccinate for the intervention participants versus the control participants will be calculated using a logistic regression model. Bivariable and multivariable logistic regression models will be used to determine the independent effect of the intervention. Results of logistic regression models will be expressed as odds ratios (ORs) and 95% confidence intervals (95% CIs). Measures of acceptability and satisfaction for intervention participants will be summarized using counts and sample proportions. All final statistical tests are two sided with $\alpha = 0.05$.

**Discussion**

Given that cervical cancer is one of the major causes of death among women worldwide, interventions to prevent high-risk types of HPV (HPV16 and HPV18) infection are urgently warranted. This study will be the first to evaluate whether a mobile-based approach combining theory-based education can improve HPV vaccination among females from mainland China.

Human behavior transformation is a complex process influenced by multiple factors. Therefore, theory-based interventions targeting multiple behavioral factors are needed to address the wide range of mechanisms relevant to the process of understanding HPV to receiving the 3 doses of the HPV vaccine. Promising results have been obtained from the school-based interventions for preventing cervical cancer in adolescents. This used the Health Belief Model (HBM) as a theoretical framework to examine the impact of intervention on HPV vaccination in 741 adolescents aged 16 years [18, 36]. The study design contained four elements: school-based questionnaire has not been fully validated among Chinese female college students.

To summarize, this is the first RCT to investigate theory-based interventions to improve human papillomavirus vaccination uptake among Chinese female college students. This multicenter RCT study will contribute to a growing research field which assesses the effectiveness of mobile-based, school-targeted and theoretically guided interventions for promoting HPV vaccination in adolescents.

Alternatively, the results of DiClemente's study, which made the vaccination free-of-charge for the intervention group so as to eliminate certain accessibility barriers in a clinical setting, did not show a statistically significant result [35]. Their findings suggest that objective factors, such as vaccine cost and accessibility, may not significantly contribute to poor vaccine uptake. In contrast, a low perceived susceptibility to the HPV infection may help explain the low vaccination rates observed in this study. Furthermore, both the limited sample size and inappropriate recruitment period that conflicted with adolescent's school hours (9 am-5 pm) had a negative impact on HPV vaccination uptake. Finally, the 12-min media program was likely too short to affect the participants' desire to receive the HPV vaccine. Thus, similar to the DiClemente's trial, the current study will be conducted based on the IMB theory. At the same time, however, we will avoid the weaknesses of the above research, as the methodology section demonstrates.

In the current study, we will choose the female college students as the study participants because of their increasing sexual demand and the spread of HPV infection among them [20–22]. School-based interventions are employed as they have been proved suitable and effective in promoting the HPV vaccine in previous studies [16, 18]. In addition, the IMB model is used due to previously beneficial predictions and health behavior promotions across many health areas [35–37]. The Fisher's recommendations have also been employed due to their usefulness in designing the IMB theory-based interventions to improve HPV vaccination rates in the future. Furthermore, the 7-day education via the mobile app is in line with the preferences of young people [23, 24]. Finally, taking the regional differences into account, our trial will set up seven sub-centers in accordance with the seven geographical divisions in China.

However, this study has potential limitations: First, there is no exact baseline data on vaccination rates to calculate an appropriate sample size, since the HPV vaccine has just been approved in China for just 3 years. Secondly, the short follow-up period of only 6 months and the unverified 7-day education method may also lead to measurement bias. Furthermore, the IMB theory-based questionnaire has not been fully validated among Chinese female college students.

To summarize, this is the first RCT to investigate theory-based interventions to improve human papillomavirus vaccination uptake among Chinese female college students. This multicenter RCT study will contribute to a growing research field which assesses the effectiveness of mobile-based, school-targeted and theoretically guided interventions for promoting HPV vaccination in adolescents.
Appendix
Model consent form
The school of public health of Peking Union Medical College is carrying out an intervention study on HPV vaccination for Chinese female college students. This study is supported by the Innovative Engineering Program of Chinese Academy of Medical Sciences, and your participation can provide the data needed for the study. To help you understand and make a decision on whether to participate in this study, we will have a specific staff to give you a detailed introduction through this informed consent. If you have any questions, you can raise them at any time.

Human papilloma virus (HPV) is a kind of spherical DNA virus, which can cause the proliferation of squamous epithelium of human skin and mucosa, and lead to genital warts (condyloma acuminatum), cervical cancer, anal cancer, etc. Since July 2016, China has successively introduced three kinds of HPV vaccines to prevent cervical cancer, precancerous lesions and genital warts caused by HPV infection. It has been confirmed that HPV vaccine can effectively prevent the persistent infection of HPV in the world, but it is still recommended that women have cervical examination regularly.

1. Research purpose: To understand the current situation of HPV vaccination of female college students in China, to explore the customized electronic education measures based on the information-motivation-behavior skill theory (IMB), and the intervention effect on the HPV vaccination rate of female college students in China, and finally to improve the HPV vaccination rate and reduce the incidence of cervical cancer.

2. Research methods: In this study, a certain number of female college students were recruited. After senior staff asked brief screening questions, those who met the selection criteria were recruited. We will collect the changes of awareness, cognition and behavior of subjects on HPV, HPV vaccine and cervical cancer related knowledge through an mobile education intervention and regular e-questionnaire survey. You may be required to download and install the "DingTalk" mobile app, provide your Wechat account and mobile number, so that we can provide e-education and follow-up consultation services.

3. Rights and Obligations: Your participation in this study is entirely voluntary. You can choose not to participate in this study, or you can withdraw at any time without any reason, and your rights will not be affected. If you agree to participate in this study, we will conduct e-education and questionnaire survey to understand your situation about HPV related knowledge, cognition and HPV vaccination.

4. Expected risks and Countermeasures:
You have the right to refuse to answer some sensitive questions in the questionnaire, or to withdraw from the study at any time.

To provide follow-up services, your mobile number or Wechat account are required. All the above information is stored in an encrypted laptop computer and kept by a specific staff to ensure the confidentiality.

5. Expected benefits:
Through this study, the participants can better understand the knowledge about human papillomavirus (HPV), HPV vaccine and cervical cancer prevention. Meanwhile, they will get motivation and the related behavior skills to uptake HPV vaccines. The experience and achievements of the study may provide ideas in promotion of HPV vaccine among female college students, and it will contribute to cervical cancer prevention actions in China.

6. Expenses: No change.

7. Confidentiality agreement: All your personal privacy information are for research reference only. And the personal data are encoded when applying the information or results.

8. Contact information: Please contact us if you have any questions about this research, contact information: .

9. Signature of informed consent: I have correctly understood the study, I am voluntary for the research and sign the informed consent before.

Abbreviations
CIs: Confidence Intervals; FDA: Food and Drug Administration; HPV: Human Papillomavirus; IMB: Information-Motivation-Behavioral skill; OR: Odds ratio; P: Probability; RCT: Randomized Controlled Trial; US: the United States

Acknowledgements
The authors of this manuscript appreciated all the staffs from cooperative institutions and the expert from Cancer Hospital Chinese Academy of Medical Sciences for their contribution to the study.

Protocol amendments
Any modifications to the protocol which may impact on the conduct of the study will be agreed upon the University advisory committee and approved by China CDC Institutional Review Board prior to implementation. Other minor changes that have no effect on the way the study is to be conducted, which will just be agreed upon by the University advisory committee and documented in a memorandum.

Authors’ contributions
MYS, XYS and YLQ designed the study. MYS and XYS drafted the manuscript. YJ and YLL revised the manuscript. All authors approved the final version of the manuscript submitted to the journal.

Funding
This study was funded by the Innovative Engineering Program on global health policy sponsored by Chinese Academy of Medical Sciences (2017-I2M-B&R-17).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study has been approved by the Institutional Review Board of Chinese Center for Disease Control and Prevention in July 2019 (approval number: 201918). Written informed consent forms will be obtained from all participants prior to the baseline survey. The results of the study will be published in peer-reviewed journals, and the findings will be presented at academic conferences or scientific meetings.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1School of Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 DongDanSanTiao, Dongcheng District, Beijing, China. 2Department of Cancer Epidemiology, National Cancer Center / National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
2. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China. 2015. Zhonghua Zhong Liu Za Zhi. 2015;41:19–28. https://doi.org/10.7320/zrlzjz2015.03.005.
3. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. ICO/ IARC information Centre on HPV and Cancer (HPV information Centre). Human Papillomavirus and Related Diseases in China. Summary Report 17 June 2019. https://hpvcentre.net/statistics/reports/CHN.pdf. Accessed 1 Nov 2019.
4. Chen ZP, Sun XD, Cheng XD, Zhang SY, Wang HQ. Recommendations on use of human papillomavirus vaccines in adult women. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(9):879–84. https://doi.org/10.3760/cma.j.issn.0253-3766.2018.09.003.
5. WHO. WHO Position Paper on Vaccines against Human Papillomavirus (HPV). 2017. https://www.who.int/immunization/policy/position_papers/pp_hpv_may2017_presentation.pdf?ua=1. Accessed 1 Nov 2019.
6. WHO, WHO Position Paper on Vaccines against Human Papillomavirus (HPV). 2017. https://www.who.int/immunization/policy/position_papers/pp_hpv_may2017_presentation.pdf?ua=1. Accessed 1 Nov 2019.
7. Denny L, International Federation of G, Obstetrics. Safety of HPV vaccination: a FIGO statement. Int J Gynaecol Obstet. 2013;123(3):187–8. https://doi.org/10.1016/j.ijgo.2013.09.009.
8. WHO. Guide to Introducing HPV Vaccine into National Immunization Programmes. 2016. https://www.who.int/immunization/diseases/hpv/DRAFT_HPV_vaccine_intro_guides_Oct2016_web.pdf. Accessed 1 Nov 2019.
9. WHO. A world free of cervical cancer. 2018. https://www.who.int/cervical-cancer/en/. Accessed 1 Nov 2019.
10. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases-The Pink Book. Human Papillomavirus, 2018. https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html. Accessed 1 Nov 2019.
11. Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control. Lancet. 2019;393(10175):969–70. https://doi.org/10.1016/S0140-6736(18)32849-6.
12. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China. 2015. Zhonghua Zhong Liu Za Zhi. 2015;41:19–28. https://doi.org/10.7320/zrlzjz2015.03.005.
13. Liu CR, Liang H, Zhang X, Pu C, Li Q, Li QL, et al. Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China. BMC Public Health. 2015;19(1):488. https://doi.org/10.1186/s12889-015-6825-0.
14. Chang JJ, Huang R, He W, Zhang SK, Wang SM, Zhao FH, et al. Effect of an educational intervention on HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: a cross-sectional study. BMC Public Health. 2013;13:3916. https://doi.org/10.1186/1471-2458-13-916.
15. Grandahl M, Rosenblad A, Stenhammar C, Tydén T, Westerling R, Larsson M, et al. School-based intervention for the prevention of HPV among adolescents: a cluster randomised controlled study. BMJ Open. 2016;6(1):e008975. https://doi.org/10.1136/bmjopen-2015-009875.
16. Sanderson M, Canedo JR, Khebele D, Fadden MK, Harris C, Beard K, et al. Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics. BMC Public Health. 2017;17(1):158. https://doi.org/10.1186/s12889-017-4094-1.
17. Marek E, Dergez T, Rebek-Nagy G, Kriczkovics A, Kovacs K, Bozza S, et al. Adolescents’ awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary. Vaccine. 2011;29(47):8591–8. https://doi.org/10.1016/j.vaccine.2011.09.018.
18. Kollar LM, Kahn JA. Education about human papillomavirus and human papillomavirus vaccines in adolescents. Curr Opin Obstet Gynecol. 2008;20(2):79–83. https://doi.org/10.1097/GCO.0b013e328280d8c6.
19. Petty KE, Wegener DT, Fabrigar LR. Attitudes and attitude change. Ann Rev Psychol. 1997;48:609–47. https://doi.org/10.1146/annurev.psych.48.1.609.
20. Lee HY, Koopmeiners JS, Rhee TG, Ravies VH, Ahluwalia JS. Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention. J Med Internet Res. 2014;16(8):e196. https://doi.org/10.2196/jmir.3576.
21. CNNIC. A report on adolescents’ internet usage behavior in China in 2015. Beijing: China Internet Network Information Center; 2016. http://www.cnnic.net.cn/hlwfzyj/hlwxzbg/qsbgb/201608/P020160812393489128332.pdf. Accessed 1 Nov 2019.
22. Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull. 1992;111(3): 455–74.
23. Fisher WA. Understanding human papillomavirus vaccine uptake. Vaccine. 2012;30(Suppl 5):F149–F56. https://doi.org/10.1016/j.vaccine.2012.04.107.
24. Chan AW, Tetzloff JM, Altman DG, Laupaci A, Gettsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. https://doi.org/10.7326/m3149-13-201302050-00583.
25. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. https://doi.org/10.1136/bmj.c332.
26. Boutron I, Moher D, Altman DG, Schulz KE, Ravaud P, CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295–309. https://doi.org/10.7326/0003-4819-148-4-200802190-00008.
27. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 2003;14(3):300–6. https://doi.org/10.1258/095646203321605486.
28. Forster AS, McBride KA, Davies C, Stoney T, Marshall H, McGeechan K, et al. Development and validation of measures to evaluate adolescents’ knowledge about human papillomavirus (HPV), involvement in HPV vaccine decision-making, self-efficacy to receive the vaccine and fear and anxiety. Public Health. 2017;147:77–83. https://doi.org/10.1016/j.puhe.2017.02.006.
29. Kim HW. Knowledge about human papillomavirus (HPV), and health beliefs and intention to recommend HPV vaccination for girls and boys among Korean high school teachers. Vaccine. 2012;30(36):5327–34. https://doi.org/10.1016/j.vaccine.2012.06.040.
30. Gerend MA, Shephard JE. Predicting human papillomavirus vaccine uptake in young adult women: comparing the health belief model and theory of planned behavior. Ann Behav Med. 2012;44(2):171–80. https://doi.org/10.1007/s12160-012-9366-5.
31. Guvenc G, Seven M, Akuzucu A. Health belief model scale for human papilloma virus and its vaccination: adaptation and psychometric testing. J Pediatr Adolesc. Gynecol. 2016;29(3):252–8. https://doi.org/10.1016/j.jgay.2015.09.007.
35. DiClemente RJ, Murray CC, Graham T, Still J. Overcoming barriers to HPV vaccination: a randomized clinical trial of a culturally-tailored, media intervention among African American girls. Hum Vaccine Immunother. 2015; 11(12):2883–94. https://doi.org/10.1080/21645515.2015.1070996.

36. Jiang H, Chen X, Li J, Tian Z, Cheng W, Yang Y. Predictors of condom use behavior among men who have sex with men in China using a modified information-motivation-behavioral skills (IMB) model. BMC Public Health. 2019;19(1):261. https://doi.org/10.1186/s12889-019-6593-8.

37. Gao J, Wang J, Zhu Y, Yu J. Validation of an information-motivation-behavioral skills model of self-care among Chinese adults with type 2 diabetes. BMC Public Health. 2013;13:100. https://doi.org/10.1186/1471-2458-13-100.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.